Effects of tacrolimus on ischemia-reperfusion injury

Liver Transplantation

Volumn 9, Issue 2, 2003, Pages 105-116

  St Peter, Shawn D ^a   Moss, Adyr A ^a   Mulligan, David C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CALCIUM; CYCLOSPORIN A; FREE RADICAL; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; TACROLIMUS; TRANSCRIPTION FACTOR;

APOPTOSIS; CELL NUCLEUS; CELL PROTECTION; DRUG EFFECT; DRUG MECHANISM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; ISCHEMIA; MICROCIRCULATION; MITOCHONDRION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPERFUSION INJURY; RETROSPECTIVE STUDY; REVIEW;

EID: 0037322564     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50020     Document Type: Review

References (122)

1. Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, Aoki H, Imanaka H. FK506: Historical perspectives. Transplant Proc 1991;23:2713-2717.
2. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256-1265.
3. Showstack J, Katz P, Amend W, Bernstein L, Lipton H, O'Leary M, et al. The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Engl J Med 1989;321:1086-1092.
4. Oates JA, Wood AJ. The regulation of discovery and drug development. N Engl J Med 1989;320:311-312.
5. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:1000-1004.
6. Margreiter R; European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 2002;359:741-746.
7. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001;14:370-383.
8. Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002;17:141-149.
9. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002;73:775-182.
10. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, Krom RA. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997;3:1-9.
11. Sher LS, Cosenza CA, Michel J, Makowka L, Miller CM, Schwartz ME, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: A report of the US Multicenter Liver Study Group. Transplantation 1997;64:258-263.
12. Jain AB, Kashyap R, Rakela J, Starzl TE, Fung JJ. Primary adult liver transplantation under tacrolimus: More than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 1999;5:144-150.
13. Millis JM, Woodle ES, Piper JB, Bruce DS, Newell KA, Seaman DS, et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation 1996;61:1365-1369.
14. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998;66:493-499.
15. Jordan ML, Shapiro R, Gritsch HA, Egidi F, Khanna A, Vivas CA, et al. Long-term results of pancreas transplantation under tacrolimus immunosuppression. Transplantation 1999;67:266-272.
16. Ghasemian SR, Light JA, Currier C, Sasaki TM, Aquino A. Tacrolimus vs Neoral in renal and renal/pancreas transplantation. Clin Transplant 1999;13:123-125.
17. Peddi VR, Kamath S, Munda R, Demmy AM, Alexander JW, First MR. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Clin Transplant 1998;12:401-405.
18. Drosos AA. Newer immunosuppressive drugs: Their potential role in rheumatoid arthritis therapy. Drugs 2002;62:891-907.
19. Gupta AK, Adamiak A, Chow M. Tacrolimus: A review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002;16:100-114.
20. Mochizuki M, Ikeda E, Shirao M, Fujito S, Yoshimura K, Shimada N. Preclinical and clinical study of FK506 in uveitis. Curr Eye Res 1992;11(suppl):S87-S95.
21. Sandborn WJ. Transcending conventional therapies: The role of biologic and other novel therapies. Inflamm Bowel Dis 2001;7(suppl 1):S9-S16.
22. Frantz B, Nordby EC, Bren G, Steffan N, Paya CV, Kincaid RL, et al. Calcineurin acts in synergy with PMA to inactivate IkappaB/MAD3, an inhibitor of NF-kappaB. EMBO J 1994;13:861-870.
23. Bultynck G, De Smedt H, Parys JB, Callewaert G, Missiaen L. Washing out of lipophilic compounds induces a transient increase in the passive Ca(2+) leak in permeabilized A7r5 cells. Cell Calcium 2002;31:229-233.
24. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A 1992;89:3686-3690.
25. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 1990;87:9231-9235.
26. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 1989;246:1617-1620.
27. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-760.
28. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341:755-757.
29. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:283-287.
30. Xu X, Su B, Barndt RJ, Chen H, Xin H, Yan G, et al. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. Transplantation 2002;73:1835-1838.
31. Dhar DK, Nagasue N, Uchida M, Takemoto Y, Yoshimura H, Yamanoi A, et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. Transplantation 1993;56:1555-1558.
32. Dhar DK, Nagasue N, Kimoto T, Uchida M, Takemoto Y, Nakamura T. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. Transplantation 1992;54:583-588.
33. Sakr MF, Hassanein TI, Zetti GM, Van Thiel DH. FK506 ameliorates the hepatic injury associated with ischemia. Life Sci 1990;47:687-691.
34. Sakr MF, Zetti GM, Hassanein TI, Farghali H, Nalesnik MA, Gavaler JS, et al. FK 506 ameliorates the hepatic injury associated with ischemia and reperfusion in rats. Hepatology 1991;13:947-951.
35. Kawano K, Bowers JL, Clouse ME. Protective effect of FK506 on hepatic injury following cold ischemic preservation and transplantation: Influence on hepatic microcirculation. Transplant Proc 1995;27:362-363.
36. Vollmar B, Glasz J, Leiderer R, Post S, Menger MD. Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction in warm ischemia-reperfusion. Am J Pathol 1994;145:1421-1431.
37. Wakabayashi H, Karasawa Y, Tanaka S, Kokudo Y, Maeba T. The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. Surg Today 1994;24:994-1002.
38. Soda Y, el-Assal ON, Yu L, Nagasue N. Suppressed endothelin-1 production by FK506 and cyclosporin A in ischemia/reperfusion of rat small intestine. Surgery 1999;125:23-32.
39. Kaibori M, Sakitani K, Oda M, Kamiyama Y, Masu Y, Nishizawa M, et al. Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-kappaB activation in rat hepatocytes. J Hepatol 1999;30:1138-1145.
40. Oyanagui Y. Nitric oxide and hydrogen peroxide-mediated gene expression by glucocorticoids and FK506 in histamine paw edema of mice. Life Sci 1994;55:PL177-PL185.
41. Schroeder RA, Kuo PC. Local consequences of reperfusion following transplantation. In: Grace PA, Mathie RT (eds). Ischaemia-reperfusion injury. London: Blackwell, 1999:113-122.
42. McKeown CM, Edwards V, Phillips MJ, Harvey PR, Petrunka CN, Strasberg SM. Sinusoidal lining cell damage: The critical injury in cold preservation of liver allografts in the rat. Transplantation 1988;46:178-191.
43. St. Peter SD, Imber CJ, Friend PJ. Kidney and liver preservation by perfusion. Lancet 2002;359:604-613.
44. Garcia-Criado FJ, Palma-Vargas JM, Valdunciel-Garcia JJ, Toledo AH, Misawa K, Gomez-Alonso A, et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. Transplantation 1997;64:594-598.
45. Kawano K, Kim YI, Goto S, Ono M, Kobayashi M. A protective effect of FK506 in ischemically injured rat livers. Transplantation 1991;52:143-145.
46. Kawano K, Bowers JL, Kim YI, Tatsuma T, Kitano S, Kobayashi M, Clouse ME. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. Transplant Proc 1996;28:1902-1903.
47. 31P-MRS) in 40 recipient patients. Transplant Proc 1989;21:1266-1267.
48. Kaibori M, Inoue T, Tu W, Oda M, Kwon A-H, Kamiyama Y, Okomura T. FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes. Lif Sci 2001;69:17-26.
49. Nakai A, Kuroda S, Kristian T, Siesjo BK. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. Neurobiol Dis 1997;4:288-300.
50. Zini R, Simon N, Morin C, Thiault L, Tillement JP. Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. Lif Sci 1998;63:357-368.
51. 2 and antioxidants have opposite effects on activation of NF-kappaB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993;12:2005-2015.
52. LeMasters JJ, Thurman R. Hypoxia and reperfusion injury to liver. Prog Liver Dis 1993;11:85-114.
53. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992;53:957-978.
54. Dhar DK, Takemoto Y, Nagasue N, Uchida M, Ono T, Nakamura T. FK506 maintains cellular calcium homeostasis in ischemia-reperfusion injury of the canine liver. J Surg Res 1996;60:142-146.
55. Bonventre JV, Weinberg JM. Kidney preservation ex vivo for transplantation. Annu Rev Med 1992;43:523-553.
56. Kurose I, Anderson DC, Miyasaka M, Tamatani T, Paulson JC, Todd RF, Rusche JR. Molecular determinants of reperfusion-induced leukocyte adhesion and vascular protein leakage. Circ Res 1994;74:336-343.
57. Khandoga A, Biberthaler P, Enders G, Axmann S, Hutter J, Messmer K, Krombach F. Platelet adhesion mediated by fibrinogen-intercellular adhesion molecule-1 binding induces tissue injury in the postischemic liver in vivo. Transplantation 2002;74:681-687.
58. Zhou W, McCollum MO, Levine BA, Olson MS. Inflammation and platelet-activating factor production during hepatic ischemia/reperfusion. Hepatology 1992;16:1236-1240.
59. Haines DD, Bak I, Ferdinandy P, Mahmoud FF, Al-Harbi SA, Blasig TE, Tosaki A. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. J Cardiovasc Pharmacol 2000;35:37-44.
60. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-434.
61. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: Vascular adhesion molecules. FASEB J 1995;9:866-873.
62. Altavilla D, Squadrito F, Ioculano M, Canale P, Campo GM, Zingarelli B, Caputi AP. E-Selectin in the pathogenesis of experimental myocardial ischemia-reperfusion injury. Eur J Pharmacol 1994;270:45-51.
63. Squadrito F, Saitta A, Altavilla D, Ioculano M, Canale P, Campo GM, et al. Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. Inflamm Res 1996;45:14-19.
64. Altavilla D, Squadrito F, Canale P, Ioculano M, Campo GM, Squadrito G, et al. E-Selectin involvement in the pathogenesis of splanchnic artery occlusion shock. Eur J Pharmacol 1995;272:223-229.
65. Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, Arlotta M, et al. Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia-reperfusion injury. J Mol Cell Cardiol 2000;32:429-440.
66. Garcia-Criado FJ, Lozano-Sanchez F, Fernandez-Regalado J, Valdunciel-Garcia JJ, Parreno-Manchado F, Silva-Benito I, et al. Possible tacrolimus action mechanisms in its protector effects on ischemia-reperfusion injury. Transplantation 1998;66:942-943.
67. Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990;85:1936-1943.
68. Colletti LM, Kunkel SL, Walz A, Burdick MD, Kunkel RG, Wilke CA, Strieter RM. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 1996;23:506-514.
69. Remick DG, Colletti LM, Scales WA, McCurry KR, Campbell DA Jr. Cyrokines and extrahepatic sequelae of ischemia-reperfusion injury to the liver. Ann NY Acad Sci 1994;723:271-283.
70. Jaeschke H, Farhood A, Smith CW. Neutrophils contribute to ischemia/reperfusion injury in rat liver in vivo. FASEB J 1990;4:3355-3359.
71. Sakr MF, McClain CJ, Gavaler JS, Zetti GM, Starzl TE, Van Thiel DH. FK506 pretreatment is associated with reduced levels of tumor necrosis factor and interleukin-6 following hepatic ischemia/reperfusion. J Hepatol 1993;17:301-307.
72. Kawano K, Kim YI, Kai T, Ishii T, Tatsuma T, Morimoto A, et al. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: In vivo demonstration for suppression of TNF-α production in response to endotoxemia. Eur Surg Res 1994;26:108-115.
73. Yang CW, Ahn HJ, Han HJ, Kim WY, Li C, Shin MJ, et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. Transplantation 2001;72:1753-1759.
74. Krishnadasan B, Naidu B, Rosengart M, Farr AL, Barnes A, Verrier ED, Mulligan MS. Decreased lung ischemia-reperfusion injury in rats after preoperative administration of cyclosporine and tacrolimus. J Thorac Cardiovasc Surg 2002;123:756-767.
75. Okamoto S, Mukaida N, Yasumoto K, Rice N, Ishikawa Y, Horiguchi H, et al. The interleukin-8, AP1 and κB-like sites are genetic and targets of FK506-sensitive pathway accompanied by calcium mobilization. J Biol Chem 1994;269:8582-8589.
76. Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K. Involvement of a NF-kappaB-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 1990;10:561-568.
77. Read MA, Whitley MZ, Gupta S, Pierce JW, Best J, Davis RJ, Collins T. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 1997;272:2753-2761.
78. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappaB and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
79. Read MA, Whitley MZ, Williams AJ, Collins T, NF-kappaB and IkappaBalpha: An inducible regulatory system in endothelial activation. J Exp Med 1994;179:503-512.
80. Shu HB, Agranoff AB, Nabel EG, Leung K, Duckett CS, Neish AS, et al. Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappaB subunits in endothelial and epithelial cells. Mol Cell Biol 1993;13:6283-6289.
81. Kawai M, Nishikomori R, Jung EY, Tai G, Yamanaka C, Mayumi M, Heike T. Pyrrolidine dithiocarbamate inhibits intercellular adhesion molecule-1 biosynthesis induced by cytokines in human fibroblasts. J Immunol 1995;154:2333-2341.
82. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IkappaBalpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-286.
83. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-kappaB activity through induction of IkappaB synthesis. Science 1995;270:286-290.
84. Baldwin AS. The NF-kappaB and the IkappaB proteins: New discoveries and insights. Ann Rev Immunol 1996;14:649-681.
85. Lille ST, Lefler SR, Mowlavi A, Suchy H, Boyle EM Jr, Farr AL, et al. Inhibition of the initial wave of NF-kappaB activity in rat muscle reduces ischemia/reperfusion injury. Muscle Nerve 2001;24:534-541.
86. Garrity PA, Chen D, Rothenberg EV, Wold BJ. Interleukin-2 transcription is regulated in vivo at the level of coordinated binding of both constitutive and regulated factors. Mol Cell Biol 1994;14:2159-2169.
87. Suzuki S, Toledo-Pereyra LH, Rodriguez F, Lopez F. Role of Kupffer cells in neutrophil activation and infiltration following total hepatic ischemia and reperfusion. Circ Shock 1994;42:204-209.
88. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ. Role of neutrophils during the first 24 hours after liver ischemia and reperfusion injury. Transplant Proc 1994;26:3695-3700.
89. Flick MR, Perel A, Staub NC. Leukocytes are required for increased lung microvascular permeability after microembolization in sheep. Circ Res 1981;48:344-351.
90. Weiss SJ, Curnutte JT, Regiani S. Neutrophil-mediated solubilization of the subendothelial matrix: Oxidative and nonoxidative mechanisms of proteolysis used by normal and chronic granulomatous disease phagocytes. J Immunol 1986;136:636-641.
91. Weiss SJ, Regiani S. Neutrophils degrade subendothelial matrices in the presence of alpha-1-proteinase inhibitor. Cooperative use of lysosomal proteinases and oxygen metabolites. J Clin Invest 1984;73:1297-1303.
92. 2 metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs. J Appl Physiol 1986;61:2224-2229.
93. Ohmori M, Kobayashi E, Harada K, Kitoh Y, Mizuta K, Uchida H, et al. Do immunosuppressants directly affect neutrophils, resulting in protection of the liver against ischemia-reperfusion injury? Transplantation 1998;66:940-941.
94. Kubes P, Hunter J, Granger DN. Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat. Dig Dis Sci 1991;36:1469-1472.
95. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993;55:1265-1272.
96. Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T. Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart. J Cardiovasc Pharmacol 1993;21:448-454.
97. Hendey B, Klee CB, Maxfield FR. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. Science 1992;258:296-299.
98. Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science 1992;256:1315-1318.
99. Ning YM, Sanchez ER. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J Biol Chem 1993;268:6073-6076.
100. Bernardi P. Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol Rev 1999;79:1127-1155.
101. Lemasters JJ. The mitochondrial permeability transition and the calcium, oxygen and pH paradoxes: One paradox after another. Cardiovasc Res 1999;44:470-473.
102. Nishimura Y, Romer LH, Lemasters JJ. Mitochondrial dysfunction and cytoskeletal disruption during chemical hypoxia to cultured rat hepatic sinusoidal endothelial cells: The pH paradox and cytoprotection by glucose, acidotic PH, and glycine. Hepatology 1998;27:1039-1049.
103. 2+ overload. Cardiovasc Res 1999;44:556-567.
104. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. FASEB J 1995;9:1277-1287.
105. Salvesen GS, Dixit VM. Caspases: Intracellular signaling by proteolysis. Cell 1997;91:443-446.
106. Lemasters JJ. V. Necrapoptosis and the mitochondrial permeability transition: Shared pathways to necrosis and apoptosis. Am J Physiol 1999;276:G1-G6.
107. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A 1993;90:9808-9812.
108. Kong G, Kim EK, Kim WS, Lee YW, Lee JK, Paik SW, et al. Inducible nitric oxide synthase (iNOS) immunoreactivity and its relationship to cell proliferation, apoptosis, angiogenesis, clinicopathologic characteristics, and patient survival in pancreatic cancer. Int J Pancreatol 2001;29:133-140.
109. Leist M, Single B, Naumann H, Fava E, Simon B, Kuhnle S, Nicotera P. Inhibition of mitochondrial ATP generation by nitric oxide switches apoptosis to necrosis. Inhibition of mitochodrial ATP generation by nitric oxide switches apoptosis to necrosis. Exp Cell Res 1999;249:396-403.
110. Qian T, Herman B, Lemasters JJ. The mitochondrial permeability transition mediates both necrotic and apoptotic death of hepatocytes exposed to Br-A23187. Toxicol Appl Pharmacol 1999;154:117-125.
111. Bessho R, Matsubara K, Kubota M, Kuwakado K, Hirota H, Wakazono Y, et al. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappaB (NF-kappaB) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem Pharmacol 1994;48:1883-1889.
112. Khan NA, Sotelo J. Heat shock stress is deleterious to CNS cultured neurons microinjected with anti-HSP70 antibodies. Biol Cell 1989;65:199-202.
113. Fujio N, Hatayama T, Kinoshita H, Yukioka M. Induction of mRNAs for heat shock proteins in livers of rats after ischemia and partial hepatectomy. Mol Cell Biochem 1987;77:173-177.
114. Sciandra JJ, Subjeck JR, Hughes CS. Induction of glucose-regulated proteins during anaerobic exposure and of heat-shock proteins after reoxygenation. Proc Natl Acad Sci U S A 1984;81:4843-4847.
115. Saad S, Kanai M, Awane M, Yamamoto Y, Morimoto T, Isselhard W, et al. Protective effect of heat shock pretreatment with heat shock protein induction before hepatic warm ischemic injury cause by Pringle's maneuver. Surgery 1995;118:510-516.
116. Kume M, Yamamoto Y, Saad S, Gomi T, Kimoto S, Shimabukuro T, et al. Ischemic preconditioning of the liver in rats: Implications of heat shock protein induction to increase tolerance of ischemia-reperfusion injury. J Lab Clin Med 1996;128:251-258.
117. Marber MS, Mestril R, Chi SH, Sayen MR, Yellon DM, Dillmann WH. Overexpression of the rat inducible 70-kD heat stress protein in a transgenic mouse increases the resistance of the heart to ischemic injury. J Clin Invest 1995;95:1446-1456.
118. Starzl TE, Porter KA, Mazzaferro V, Todo S, Fung J, Francavilla A. Hepatotrophic effects of FK506 in dogs. Transplantation 1991;51:67-70.
119. Mazzaferro V, Scotti-Foglieni CL, Porter KA, Trejo-Bellido J, Carrieri G, Todo S, et al. Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc 1990;22:93-95.
120. Kahn D, Lai HS, Romovacek H, Makowka L, Van Thiel D, Starzl TE. Cyclosporine A augments the regenerative response after partial hepatectomy in the rat. Transplant Proc 1988; 20(suppl 3):S850-S852.
121. Kim YI, Salvini P, Auxilia F, Calne RY. Effect of cyclosporin A on hepatocyte proliferation after partial hepatectomy in rats: Comparison with standard immunosuppressive agents. Am J Surg 1988;155:245-249.
122. St. Peter SD, Post DJ, Rodriguez-Davalos MI, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transpl 2003;9:144-149.